VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)

NCT04166383 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

14

Enrollment

NIH

Sponsor class

Stopped Interim analysis indicated limited efficacy

Conditions

Metastatic Colorectal Cancer
Colorectal Neoplasms
Colorectal Carcinoma
Colorectal Cancer With Hepatic Metastases
Colorectal Tumors

Interventions

BIOLOGICAL: Vascular Biogenics (VB)-111
DRUG: Nivolumab

Sponsor

National Cancer Institute (NCI)